BACKGROUND: We conducted a retrospective review of the dose, @entity137 , and efficacy of second line @entity136 plus nab- @entity1311 (G  +  Nab-P) after FOLFIRINOX in @entity1 with metastatic and locally advanced unresectable @entity788 . METHODS: In this retrospective study, we included all @entity1 with locally advanced unresectable or metastatic @entity788 who were treated at Yale Cancer Center with G  +  Nab-P between 12/2011 and 12/2013 after receiving first line FOLFIRINOX. For each @entity1 , demographics, prior therapy, doses of G  +  Nab-P (cumulative doses and dose intensity relative to full dose G  +  Nab-P), hematologic @entity137 , best response by RECIST, time to treatment failure (TTF), and survival were compiled. Median TTF and overall survival (OS) were calculated by Kaplan-Meier method. RESULTS: 28 @entity1 were treated with G  +  Nab-P after first line FOLFIRINOX. The median TTF was 12.0  weeks (range 2.0-36.0), and the median OS was 23.0  weeks (range 2.1-85.4). Five @entity1 had a partial response (response rate 17.9  %), and 28.6  % of @entity1 had stable disease for >= 7  weeks. A decline in CA 19-9 and CEA by >30  % was observed in 13 (46.4  %) and 11 (39.3  %) @entity1 , respectively. The median relative dose intensities were 62.4 and 57.5  % for G and Nab-P, respectively. Grade >= 3 hematologic @entity137 included @entity1398 in 17.9  %, @entity417 in 25.0  %, and @entity882 in 25.0  % of @entity1 . CONCLUSIONS: Second line G  +  Nab-P following FOLFIRINOX is feasible, and demonstrated modest activity and clinical benefit in advanced @entity788 . The optimum sequencing and dosing of these active regimens warrants further evaluation in prospective trials.

XXXX plus nab-paclitaxel for advanced @entity788 after first-line FOLFIRINOX: single institution retrospective review of efficacy and @entity137 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']
